4D Molecular Therapeutics Inc (NAS:FDMT) Stock News, Headlines & Updates
4D Molecular Therapeutics Inc Stock News from GuruFocus
- 1
Jun 24, 2024
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
Marketwired • 7:00am
Jun 18, 2024
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
Marketwired • 7:00am
Jun 06, 2024
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
Marketwired • 7:00am
Jun 04, 2024
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
Marketwired • 7:00am
Jun 03, 2024
4DMT to Participate in Upcoming Investor Conferences
Marketwired • 7:00am
May 30, 2024
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47?? European Cystic Fibrosis Conference
Marketwired • 7:00am
May 10, 2024
4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections
GuruFocus Research • 11:48am
May 09, 2024
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
Marketwired • 4:00pm
May 07, 2024
4DMT to Participate in Upcoming Investor Conference
Marketwired • 7:00am
May 01, 2024
4DMT Announces Presentations at ARVO 2024 Annual Meeting
Marketwired • 7:00am
Apr 04, 2024
4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
GuruFocus Research • 11:30pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news